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Fosfomycin in vitro resistance of Escherichia coli 
from the community
It is common practice in many places all over 
Brazil to use fosfomycin in the treatment of 
uncomplicated urinary tract infections, al-
though resistance profi le is not currently 
well-known in our country. 
We would like to report the fi ndings of in 
vitro activity of fosfomycin against 240 non-
duplicate consecutive E. coli strains isolated 
from community urinary samples (> 105 CFU/
mL in October 2009) from Curitiba (Paraná, 
Brazil). Susceptibility test were performed 
according to CLSI, using disk diffusion with 
200 mg of fosfomycin disk with zone diam-
eter breakpoint as recommended by CLSI.1 
Clinical data were not evaluated and no sta-
tistical analysis was performed, considering 
the descriptive nature of the study.
The susceptibility of E. coli to fosfomycin was 
98.8% and to other antibiotics ranged from 66.3 
- 99.2% as follows: sulfamethoxazole (66.3%), 
nalidixic acid (78.3%), quinolones (81.3%, in-
cluding ciproﬂ oxacin, levoﬂ oxacin and nor-
ﬂ oxacin), amoxicillin/clavulanic acid (88.7%), 
nitrofurantoin (99.2%) and ceftriaxone (99.2%).
In the present study E. coli isolates from 
patients with urinary infection were highly 
susceptible to fosfomycin. These data sug-
gest that fosfomycin may be a good alterna-
tive for fi rst line antimicrobial treatment of 
uncomplicated low urinary tract infections.2 
It is well-known that variations in bacterial 
resistance patterns for Escherichia coli occur 
amongst different populations.3 It is manda-
tory for clinicians to be constantly aware of 
the local bacterial resistance profi les in order 
to update empirical antimicrobial regimens. 
Fosfomycin also seems to be a reasonable 
option for bacteria other than E. coli, such 
as Enterococcus.4 In our area, fosfomycin is a 
good option, but this cannot be extrapolated 
to other regions of the country. On going sur-
veillance studies are needed in the country.
[Braz J Infect Dis 2011;15(1):96]©Elsevier Editora Ltda.
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